Question 1

Men who are prescribed phosphodiesterase type 5 (PDE-5) inhibitors for erectile dysfunction should be educated regarding the adverse effects of the drug which include:

Accepted Answer

A)  Hearing loss 
B)  Hypotension 
C)  Delayed ejaculation 
D)  Dizziness 
A)  Hearing loss 
B)  Hypotension 
C)  Delayed ejaculation 
D)  Dizziness A

Question 2

Male patients who should not be prescribed phosphodiesterase type 5 (PDE-5) inhibitors include:

Accepted Answer

A)  Diabetics 
B)  Those who have had an acute myocardial infarction in the past 6 months 
C)  Patients who are deaf 
D)  Patients under age 60 years of age 
A)  Diabetics 
B)  Those who have had an acute myocardial infarction in the past 6 months 
C)  Patients who are deaf 
D)  Patients under age 60 years of age B

Question 3

The factor that has the greatest effect on males developing male sexual characteristics is:

Accepted Answer

A)  Cultural beliefs 
B)  Effective male role models 
C)  Adequate intake of testosterone in the diet 
D)  Androgen production 
A)  Cultural beliefs 
B)  Effective male role models 
C)  Adequate intake of testosterone in the diet 
D)  Androgen production D

Question 4

Some research supports that testosterone replacement therapy may be indicated in which of the following diagnoses in men?

Accepted Answer

A)  Age-related decrease in cognitive functioning 
B)  Metabolic syndrome 
C)  Decreased muscle mass in aging men 
D)  All of the above 
A)  Age-related decrease in cognitive functioning 
B)  Metabolic syndrome 
C)  Decreased muscle mass in aging men 
D)  All of the above

Question 5

While on testosterone replacement, hemoglobin and hematocrit levels should be monitored. Levels suggestive of excessive erythrocytosis or abuse are:

Accepted Answer

A)  Hemoglobin 14 g/dl or hematocrit 39% 
B)  Hemoglobin 11.5 g/dl or hematocrit 31% 
C)  Hemoglobin 13 g/dl or hematocrit 38% 
D)  Hemoglobin 17.5 g/dl or hematocrit 54% 
A)  Hemoglobin 14 g/dl or hematocrit 39% 
B)  Hemoglobin 11.5 g/dl or hematocrit 31% 
C)  Hemoglobin 13 g/dl or hematocrit 38% 
D)  Hemoglobin 17.5 g/dl or hematocrit 54%

Question 6

The goal of testosterone replacement therapy is:

Accepted Answer

A)  Absence of all hypogonadism symptoms 
B)  Testosterone levels in the mid-normal range 1 week after an injection 
C)  Testosterone levels in the mid-normal range just prior to the next injection 
D)  Avoidance of high serum testosterone levels during therapy 
A)  Absence of all hypogonadism symptoms 
B)  Testosterone levels in the mid-normal range 1 week after an injection 
C)  Testosterone levels in the mid-normal range just prior to the next injection 
D)  Avoidance of high serum testosterone levels during therapy

Question 7

Monitoring of an older male patient on testosterone replacement includes:

Accepted Answer

A)  Oxygen saturation levels at every visit 
B)  Serum cholesterol and lipid profile every 3 to 6 months 
C)  Digital rectal prostate screening exam at 3 and 6 months after starting therapy 
D)  Bone mineral density at 3 months and 6 months after starting therapy 
A)  Oxygen saturation levels at every visit 
B)  Serum cholesterol and lipid profile every 3 to 6 months 
C)  Digital rectal prostate screening exam at 3 and 6 months after starting therapy 
D)  Bone mineral density at 3 months and 6 months after starting therapy

Question 8

Monitoring of male patients who are using phosphodiesterase type 5 (PDE-5) inhibitors includes:

Accepted Answer

A)  Serum fasting glucose levels 
B)  Cholesterol and lipid levels 
C)  Blood pressure 
D)  Complete blood count 
A)  Serum fasting glucose levels 
B)  Cholesterol and lipid levels 
C)  Blood pressure 
D)  Complete blood count

Question 9

When prescribing phosphodiesterase type 5 (PDE-5) inhibitors such as sildenafil (Viagra) patients should be screened for use of:

Accepted Answer

A)  Statins 
B)  Nitrates 
C)  Insulin 
D)  Opioids 
A)  Statins 
B)  Nitrates 
C)  Insulin 
D)  Opioids

Question 10

When assessing a male for hypogonadism prior to prescribing testosterone replacement, serum testosterone levels are drawn:

Accepted Answer

A)  Without regard to time of day 
B)  First thing in the morning 
C)  Late afternoon 
D)  In the evening 
A)  Without regard to time of day 
B)  First thing in the morning 
C)  Late afternoon 
D)  In the evening

Exam 49: Men As Patients

Men who are prescribed phosphodiesterase type 5 (PDE-5) inhibitors for erectile dysfunction should be educated regarding the adverse effects of the drug which include:

Male patients who should not be prescribed phosphodiesterase type 5 (PDE-5) inhibitors include:

The factor that has the greatest effect on males developing male sexual characteristics is:

Some research supports that testosterone replacement therapy may be indicated in which of the following diagnoses in men?

While on testosterone replacement, hemoglobin and hematocrit levels should be monitored. Levels suggestive of excessive erythrocytosis or abuse are:

The goal of testosterone replacement therapy is:

Monitoring of an older male patient on testosterone replacement includes:

Monitoring of male patients who are using phosphodiesterase type 5 (PDE-5) inhibitors includes:

When prescribing phosphodiesterase type 5 (PDE-5) inhibitors such as sildenafil (Viagra) patients should be screened for use of:

When assessing a male for hypogonadism prior to prescribing testosterone replacement, serum testosterone levels are drawn:

The Role of the Nurse Practitioner

Review of Basic Principles of Pharmacology

Rational Drug Selection

Legal and Professional Issues in Prescribing

Adverse Drug Reactions

Factors That Foster Positive Outcomes

Cultural and Ethnic Influences in Pharmacotherapeutics

An Introduction to Pharmacogenomics

Nutrition and Nutraceuticals

Herbal Therapy and Nutritional Supplements

Information Technology and Pharmacotherapeutics

Pharmacoeconomics

Over-The-Counter Medications

Drugs Affecting the Autonomic Nervous System

Drugs Affecting the Central Nervous System

Drugs Affecting the Cardiovascular and Renal Systems

Drugs Affecting the Respiratory System

Drugs Affecting the Hematopoietic System

Drugs Affecting the Immune System

Drugs Affecting the Gastrointestinal System

Drugs Affecting the Endocrine System

Drugs Affecting the Reproductive System

Drugs Affecting the Integumentary System

Drugs Used in Treating Infectious Diseases

Drugs Used in Treating Inflammatory Processes

Drugs Used in Treating Eye and Ear Disorders

Anemia

Chronic Stable Angina and Low-Risk Unstable Angina

Anxiety and Depression

Asthma and Chronic Obstructive Pulmonary Disease

Contraception

Dermatologic Conditions

Diabetes Mellitus

Gastroesophageal Reflux and Peptic Ulcer Disease

Headaches

Heart Failure

Human Immunodeficiency Virus Disease and Acquired Immunodeficiency Syndrome

Hormone Replacement Therapy and Osteoporosis

Hyperlipidemia

Hypertension

Hyperthyroidism and Hypothyroidism

Pneumonia

Smoking Cessation

Sexually Transmitted Infections and Vaginitis

Tuberculosis

Upper Respiratory Infections, Otitis Media, and Otitis Externa

Urinary Tract Infections

Women As Patients

Children As Patients

Geriatric Patients

Pain Management: Acute and Chronic Pain

Filters